Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendorfer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boultwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, Maciejewski JP. Adema V, et al. EBioMedicine. 2022 Jun;80:104059. doi: 10.1016/j.ebiom.2022.104059. Epub 2022 May 23. EBioMedicine. 2022. PMID: 35617825 Free PMC article.
Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G, Luño E, Cañizo C, de la Serna J, Ardanaz M, Marco V, Collado R, Grau J, Montoro J, Mallo M, Vallespí T. Valcárcel D, et al. Among authors: adema v. J Clin Oncol. 2013 Mar 1;31(7):916-22. doi: 10.1200/JCO.2012.41.6073. Epub 2013 Jan 14. J Clin Oncol. 2013. PMID: 23319689
Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?
Ademà V, Hernández JM, Abáigar M, Lumbreras E, Such E, Calull A, Dominguez E, Arenillas L, Mallo M, Cervera J, Marugán I, Tormo M, García F, González T, Luño E, Sanzo C, Martín ML, Fernández M, Costa D, Blázquez B, Barreña B, Marco F, Batlle A, Buño I, Martínez-Laperche C, Noriega V, Collado R, Ivars D, Carbonell F, Vallcorba I, Melero J, Delgado E, Vargas MT, Grau J, Salido M, Espinet B, Melero C, Florensa L, Pedro C, Solé F. Ademà V, et al. Leuk Res. 2013 Apr;37(4):416-21. doi: 10.1016/j.leukres.2012.12.010. Epub 2013 Jan 18. Leuk Res. 2013. PMID: 23337401
Paraffin treasures: do they last forever?
Ademà V, Torres E, Solé F, Serrano S, Bellosillo B. Ademà V, et al. Biopreserv Biobank. 2014 Aug;12(4):281-3. doi: 10.1089/bio.2014.0010. Epub 2014 Jul 30. Biopreserv Biobank. 2014. PMID: 25075953
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Schneider RK, et al. Among authors: adema v. Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18. Cancer Cell. 2014. PMID: 25242043 Free PMC article.
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.
Adema V, Larráyoz MJ, Calasanz MJ, Palomo L, Patiño-García A, Agirre X, Hernández-Rivas JM, Lumbreras E, Buño I, Martinez-Laperche C, Mallo M, García O, Álvarez S, Blazquez B, Cervera J, Luño E, Valiente A, Vallespí MT, Arenillas L, Collado R, Pérez-Oteyza J, Solé F. Adema V, et al. Br J Haematol. 2015 Oct;171(1):137-41. doi: 10.1111/bjh.13355. Epub 2015 Feb 25. Br J Haematol. 2015. PMID: 25716545 Free article. No abstract available.
Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.
Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, García-Cerecedo T, López R, Talavera E, Fernández-Ruiz S, Ademà V, Marugan I, Luño E, Sanzo C, Vallespí T, Arenillas L, Marco Buades J, Batlle A, Buño I, Martín Ramos ML, Blázquez Rios B, Collado Nieto R, Vargas MT, González Martínez T, Sanz G, Solé F; Spanish Group for Mds Study (GESMD); Spanish Group for Clinical Cytogenetics (Gcecgh). Sánchez-Castro J, et al. Among authors: adema v. Leuk Lymphoma. 2015;56(11):3183-8. doi: 10.3109/10428194.2015.1028053. Epub 2015 May 12. Leuk Lymphoma. 2015. PMID: 25754580
Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.
Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L. Palomo L, et al. Among authors: adema v. Am J Hematol. 2016 Feb;91(2):185-92. doi: 10.1002/ajh.24227. Epub 2015 Dec 9. Am J Hematol. 2016. PMID: 26509444 Free article.
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L. Palomo L, et al. Among authors: adema v. Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937. Oncotarget. 2016. PMID: 27486981 Free PMC article.
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP. Negoro E, et al. Among authors: adema v. Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560106 Free PMC article. No abstract available.
52 results